Search Results
Your search for ,LTD matches 290 pages
Showing 1 - 50Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer
As reported in JAMA Oncology by Yang et al, the 3-year follow-up of the predominantly Chinese phase III RATIONALE-309 trial showed a maintained progression-free survival benefit with the addition of first-line tislelizumab to chemotherapy in patients with recurrent or metastatic nasopharyngeal...
Atezolizumab vs Placebo With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer
As reported in the Journal of Clinical Oncology by Harter et al, the final results of a European phase III trial (AGO-OVAR 2.29/ENGOT-ov34) showed no significant overall or progression-free survival benefit with the addition of atezolizumab to bevacizumab and nonplatinum chemotherapy in patients...
Oral SERD Improves Disease-Free Survival Over Standard of Care for Patients With Early-Stage Breast Cancer
The investigational oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease–free survival compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor-positive,...
Integrating Mental Health Into Cancer Care: A Community Oncology Imperative
When Julie began chemotherapy for breast cancer, her oncologist adjusted antiemetics weekly and carefully tracked neutrophil counts. Still, no one asked about the panic attacks that kept her awake at night. She told herself this was just part of cancer. It was not until she stopped showing up for...
Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
An exploratory overall survival analysis of the phase III FLAURA2 trial confirmed the overall survival benefit of adding osimertinib to chemotherapy in patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) not previously treated for advanced...
Immunotherapy Combination Active in Patients With Large B-Cell Lymphoma Who Are Not Eligible for Autologous Stem Cell Transplant
In the global phase III SUNMO trial, the combination of a bispecific antibody and an antibody-drug conjugate was compared with rituximab plus gemcitabine and oxaliplatin (GemOx) in the treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL) who were ineligible for autologous...
Glofitamab Plus Polatuzumab Vedotin in Relapsed or Refractory Large B-Cell Lymphoma
In a phase Ib/II trial reported in the Journal of Clinical Oncology, Hutchings et al found that the combination of glofitamab and polatuzumab vedotin was associated with high activity in patients with relapsed or refractory large B-cell lymphoma, including high-grade B-cell lymphoma. Study Details...
Muscle-Invasive Bladder Cancer: IMvigor011 Trial Investigates ctDNA-Guided Adjuvant PD-L1 Inhibition
Patients with muscle-invasive bladder cancer who tested positive for circulating tumor DNA (ctDNA) after cystectomy may benefit from immunotherapy with the PD-L1 inhibitor atezolizumab compared to placebo, whereas ctDNA-negative patients may potentially be spared unnecessary treatment. These...
Metastatic ER-Positive, HER2-Negative Breast Cancer: Novel Treatment Combination Improves Progression-Free Survival
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full...
Lisaftoclax Regimens Effective in Plasma Cell Disorders
Lisaftoclax, an investigational BCL2 inhibitor, in combination with pomalidomide/dexamethasone (Pd) or daratumumab/lenalidomide/dexamethasone (DRd) led to improved outcomes for patients with relapsed or refractory multiple myeloma and for patients with AL amyloidosis, according to findings from a...
Combination Therapies for Diffuse Large B-Cell Lymphoma: 5-Year Outcomes of the POLARIX Trial
As reported in the Journal of Clinical Oncology by Morschhauser et al, the 5-year findings of the POLARIX trial showed a continued benefit with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs rituximab, cyclophosphamide, doxorubicin, vincristine,...
Dendrimer-Based SN38 Nanoparticle Shows Favorable Safety and Activity in Advanced Solid Tumors
In an early-phase study reported in the Journal of Clinical Oncology, Liu et al evaluated the safety and preliminary efficacy of DEP-SN38, a polylysine-based dendrimer-nanoparticle delivery platform for the topoisomerase 1 inhibitor SN38, in patients with advanced solid tumors. SN38 is the active...
Similar Efficacy, Improved Safety Achieved Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Cancer
The PD-1 inhibitor toripalimab in combination with an induction chemoradiotherapy regimen free of concurrent cisplatin demonstrated noninferior efficacy and superior safety compared with the same regimen plus concurrent cisplatin in patients with high-risk, locoregionally advanced nasopharyngeal...
Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Xia et al compared objective response rates seen with camrelizumab plus famitinib vs camrelizumab alone in previously treated patients with recurrent or metastatic cervical cancer. Study Details In the multicenter, open-label ...
Updated Results Confirm Benefit of Combination Regimen in BRAFV600E–Mutated Metastatic Colorectal Cancer
Patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer who receive the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab plus mFOLFOX6 (modified leucovorin, fluorouracil, and oxaliplatin) vs the current standard of care (chemotherapy ± bevacizumab) may live...
First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-H Advanced Gastric/GEJ Cancer
In a Japanese phase II study (NO LIMIT, WJOG13320G) reported in the Journal of Clinical Oncology, Kawakami et al evaluated whether first-line nivolumab plus low-dose ipilimumab showed activity in patients with microsatellite instability–high (MSI-H) advanced gastric/esophagogastric junction ...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
Everolimus Plus Lanreotide vs Everolimus Alone in Aggressive Gastroenteropancreatic Neuroendocrine Tumors
In patients with aggressive gastroenteropancreatic neuroendocrine tumors, first-line treatment with the mTOR inhibitor everolimus and the somatostatin analog lanreotide more than doubled the median progression-free survival for patients vs everolimus alone, in the phase III JCOG1901 (STARTER-NET)...
inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology...
In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers
The 2025 ASCO Gastrointestinal Cancers Symposium once again delivered a slate of high-impact studies spanning esophageal, gastric, hepatocellular, pancreatic, biliary tract, and colorectal malignancies. Experts in the field offered fresh perspectives on evolving standards of care, and investigators ...
Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment
Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...
The Death of Alexei Navalny and the Discovery of Cancer Chemotherapy
Remembering Alexi Anatolyevich Navalny: The Russian opposition leader, lawyer, anticorruption activist, and political prisoner, Alexi Navalny died in the Arctic Wolf prison in Siberia approximately 1 year ago on February 16, 2024. He was designated a Prisoner of Conscience by Amnesty...
Pertuzumab Retreatment in HER2-Positive Locally Advanced/Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed a significant benefit with the addition of pertuzumab retreatment to trastuzumab plus physician’s choice of chemotherapy (PTC) in patients with...
Trastuzumab/Pertuzumab Plus Eribulin or Taxane in Locally Advanced or Metastatic Breast Cancer
In a Japanese noninferiority phase III trial (EMERALD) reported in the Journal of Clinical Oncology, Yamashita et al found that the addition of eribulin to trastuzumab/pertuzumab (HP) was noninferior in progression-free survival vs the addition of a taxane to HP in the first-line treatment of...
Neoadjuvant Nivolumab/Ipilimumab vs Chemotherapy in Resectable NSCLC
As reported in the Journal of Clinical Oncology by Awad et al, exploratory analysis of the comparison of neoadjuvant nivolumab/ipilimumab vs chemotherapy in the phase III CheckMate 816 trial found that nivolumab/ipilimumab was associated with numerically better event-free survival in patients with...
Imlunestrant Alone or With Abemaciclib: An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer
The investigational next-generation oral selective estrogen receptor degrader (SERD) imlunestrant improved progression-free survival both as monotherapy in patients with ESR1 mutations and in combination with the CDK4/6 inhibitor abemaciclib regardless of ESR1 mutational status in patients with...
Novel Formulation Used in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting
In a Chinese phase III trial (PROFIT) reported in Journal of Clinical Oncology, Zhou et al found that mixed-formulation fosrolapitant/palonosetron (HR20013) plus dexamethasone was noninferior to individually dosed fosrolapitant plus palonosetron plus dexamethasone in preventing chemotherapy-induced ...
Toripalimab Plus Chemotherapy in First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
In a Chinese phase III trial (EXTENTORCH) reported in JAMA Oncology, Cheng et al reported that the addition of the immunoglobulin G4 PD-1–blocking antibody toripalimab to first-line chemotherapy with etoposide plus cisplatin or carboplatin (EP) improved progression-free survival among patients with ...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III -CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Scientists Develop a ‘Digital Twin’ Model to Predict Cancer Treatment Responses
Researchers have created a “digital twin” model constructed from the clinical and molecular profiles of patients with cancer that accurately predicted how a patient is likely to respond to a specific chemotherapy. The approach optimizes the treatment choice for patients using available clinical...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
Novel Cell Therapy May Offer Benefit in Patients With Relapsed or Refractory T-Cell ALL
A novel cell therapy targeting CD7 on leukemia cells may provide an effective treatment option for patients with refractory T-cell acute lymphoblastic leukemia (ALL), according to a recent study published by Oh et al in Nature Medicine. The findings highlighted the effectiveness of a new chimeric...
Atezolizumab Plus Platinum Doublet and Maintenance Niraparib for Late-Relapsing Recurrent Ovarian Cancer
As reported in the Journal of Clinical Oncology by González-Martín et al, a phase III trial (ENGOT-OV41/GEICO 69-O/ANITA) has shown no progression-free survival benefit with the addition of atezolizumab to a carboplatin doublet and maintenance niraparib in patients with recurrent ovarian cancer...
Adjuvant Nivolumab vs Placebo in Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy
As reported in the Journal of Clinical Oncology by Motzer et al, part B of the phase III CheckMate 914 trial showed no disease-free survival benefit with the adjuvant use of nivolumab vs placebo in patients with localized renal cell carcinoma at high risk of recurrence after nephrectomy. These...
NIAGARA Trial: Perioperative Durvalumab Reduced Risk of Recurrence or Death vs Neoadjuvant Chemotherapy Alone in Muscle-Invasive Bladder Cancer
Positive results from the phase III NIAGARA trial showed perioperative treatment with the PD-L1 blocker durvalumab in combination with neoadjuvant chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key...
Fam-Trastuzumab Deruxtecan-nxki in Unresectable or Metastatic HER2-Positive Solid Tumors
On April 5, 2024, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted accelerated approval for adults with unresectable or metastatic HER2-positive (immunohistochemistry 3+) solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.1 Supporting...
Resected Melanoma: Subsequent Systemic Therapy After Recurrence on Adjuvant Nivolumab
In an analysis from the phase III CheckMate 238 trial reported in the Journal of Clinical Oncology, Jeffrey Weber, MD, PhD, and colleagues found that progression-free and overall survival were improved with subsequent systemic therapy following late vs early recurrence with adjuvant nivolumab in...
Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall survival with the tyrosine kinase inhibitor atezolizumab (multiple targets, including MET, AXL, VEGFR2, RET, and FLT) plus the...
Use of Topical Diclofenac Gel to Prevent Capecitabine-Associated Hand-Foot Syndrome
In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that the nonsteroidal, anti-inflammatory topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast ...
Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer: Comparison of Agents
In a Chinese phase III trial (CRTCOESC) reported in the Journal of Clinical Oncology, Jia et al found that neither capecitabine nor XELOX (capecitabine, oxaliplatin) improved 2-year overall survival vs cisplatin/fluorouracil as part of definitive concurrent chemoradiotherapy in patients with...
Zanubrutinib in Relapsed or Refractory Follicular Lymphoma
On March 7, 2024, the Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa) was granted accelerated approval in combination with the monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.1 Supporting Efficacy...
Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer
Pain, a debilitating consequence of cancer and its treatments, is highly prevalent among patients with advanced cancer.1 Often persistent and undertreated, it is associated with poor functional and emotional well-being and typically occurs along with insomnia and fatigue.2 The use of opioids,...
Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall survival with atezolizumab plus cabozantinib vs docetaxel after checkpoint inhibitor treatment and chemotherapy in patients with...
Giredestrant in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
In the phase II acelERA BC trial reported in the Journal of Clinical Oncology, Miguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER) antagonist and degrader giredestrant did not significantly improve progression-free survival vs physician’s choice of endocrine...
Liposomal Irinotecan in First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
On February 13, 2024, the U.S. Food and Drug Administration approved liposomal irinotecan (Onivyde) for use with oxaliplatin, fluorouracil, and leucovorin in the first-line treatment of metastatic pancreatic adenocarcinoma.1 Supporting Efficacy Data Approval was based on the open-label NAPOLI 3...
Topical Diclofenac to Prevent Capecitabine-Associated Hand-Foot Syndrome
In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast or gastrointestinal cancer who were ...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
